Privacy    
 
  Citi Research Disclosures


ABCDEFGHIJKLMNOPQRSTUVWXYZ#




Disclosures Home
Conflicts Management Policy
SEBI Investor Charter & Complaint Information
SEBI Prescribed Client Terms & Conditions
Staff Conflicts
Terms of Use

 
Valuation & Risks ( AFYA ) Disclosure / Price Chart(s) / Valuation & Risk
Fundamental Equity Research
We value Afya based on a discount free cash flow model (FCFE), employing a Ke and perpetual growth assumptions of 13.9% and 5.0%, respectively, yielding a 12-month target price of US$14.0/share.

Our key risks and concerns for the target price are: 1) better/worse-than-expected operating margins; 2) occupation rate stays higher for longer or deteriorates; 3) continuing education starts to/fails to ignite sales; 4) better/worse-than-expected digital services execution; 5) faster/slower-than-expected increase in the supply of medical seats, affecting returns and margins.


If the impact on the company from any of these factors proves to be greater than we anticipate, the stock will likely have difficulty achieving our target price.

 

 

citiPrivacy
www.citigroup.com Terms, conditions, caveats, and small print
Copyright © 2025 Citi